keyword
MENU ▼
Read by QxMD icon Read
search

Ebola vaccine

keyword
https://www.readbyqxmd.com/read/28719299/conventional-wisdom-versus-actual-outcomes-challenges-in-the-conduct-of-an-ebola-vaccine-trial-in-liberia-during-the-international-public-health-emergency
#1
Gregg S Larson, Beth R Baseler, Marie L Hoover, Jerome F Pierson, Jemee K Tegli, Melvin P Johnson, Mark W S Kieh, Laura A McNay, Wissedi Sio Njoh
Clinical trials are challenging endeavors. Planning and implementing an investigational vaccine trial in Liberia, in the midst of an Ebola virus disease (EVD) epidemic that World Health Organization classified a public health emergency of international concern, presented extraordinary challenges. Normally, years of preparation and a litany of tasks lay the groundwork for a successful, randomized, blinded, placebo-controlled trial focused on safety and efficacy. Difficult research settings, unpredictable events, and other unique circumstances can add complexity...
July 2017: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/28716555/attitudes-about-vaccines-to-prevent-ebola-virus-disease-in-guinea-at-the-end-of-a-large-ebola-epidemic-results-of-a-national-household-survey
#2
Kathleen L Irwin, Mohamed F Jalloh, Jamaica Corker, Barry Alpha Mahmoud, Susan J Robinson, Wenshu Li, Nyuma E James, Musa Sellu, Mohammad B Jalloh, Alpha Ahmadou Diallo, LaRee Tracy, Rana Hajjeh, Amanda VanSteelandt, Rebecca Bunnell, Lise Martel, Pratima L Raghunathan, Barbara Marston
INTRODUCTION: In 2014-2016, an Ebola epidemic devastated Guinea; more than 3800 cases and 2500 deaths were reported to the World Health Organization. In August 2015, as the epidemic waned and clinical trials of an experimental, Ebola vaccine continued in Guinea and neighboring Sierra Leone, we conducted a national household survey about Ebola-related knowledge, attitudes, and practices (KAP) and opinions about "hypothetical" Ebola vaccines. METHODS: Using cluster-randomized sampling, we selected participants aged 15+ years old in Guinea's 8 administrative regions, which had varied cumulative case counts...
July 14, 2017: Vaccine
https://www.readbyqxmd.com/read/28708962/open-label-phase-i-clinical-trial-of-ad5-ebov-in-africans-in-china
#3
Lihua Wu, Zhe Zhang, Hainv Gao, Yuhua Li, Lihua Hou, Hangping Yao, Shipo Wu, Jian Liu, Ling Wang, You Zhai, Huilin Ou, Meihua Lin, Xiaoxin Wu, Jingjing Liu, Guanjing Lang, Qian Xin, Guolan Wu, Li Luo, Pei Liu, Jianzhong Shentu, Nanping Wu, Jifang Sheng, Yunqing Qiu, Wei Chen, Lanjuan Li
BACKGROUND: To determine the safety and immunogenicity of a novel recombinant adenovirus type 5 vector based Ebola virus disease vaccine (Ad5-EBOV) in Africans in China. METHODS: A phase 1, dose-escalation, open-label trial was conducted. 61 healthy Africans were sequentially enrolled, with 31 participants receiving one shot intramuscular injection and 30 participants receiving a double-shot regimen. Primary and secondary end points related to safety and immunogenicity were assessed within 28 days after vaccination...
July 14, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28706039/when-an-emerging-disease-becomes-endemic
#4
REVIEW
Graham F Medley, Anna Vassall
Epidemics, such as HIV in the early 1980s and Ebola in 2014, inspire decisive government investment and action, and individual and societal concern, sometimes bordering on panic. By contrast, endemic diseases, such as HIV in 2017 and tuberculosis, struggle to maintain the same attention. For many, the paradox is that endemic disease, in its totality, continues to impose a far higher public health burden than epidemic disease. Overall, the swift political response to epidemics has resulted in success. It has proven possible to eradicate epidemic diseases, often without the availability of vaccines and other biomedical technologies...
July 14, 2017: Science
https://www.readbyqxmd.com/read/28699812/epitope-mapping-of-ebola-virus-dominant-and-subdominant-glycoprotein-epitopes-facilitates-construction-of-an-epitope-based-dna-vaccine-able-to-focus-the-antibody-response-in-mice
#5
Daniel A J Mitchell, Lesley C Dupuy, Mariano Sanchez-Lockhart, Gustavo Palacios, Jaap W Back, Katya Shimanovskaya, Sidhartha Chaudhury, Daniel R Ripoll, Anders Wallqvist, Connie S Schmaljohn
We performed epitope mapping studies on the major surface glycoprotein (GP) of Ebola virus (EBOV) using Chemically Linked Peptides on Scaffolds (CLIPS), which form linear and potential conformational epitopes. This method identified monoclonal antibody epitopes and predicted additional epitopes recognized by antibodies in polyclonal sera from animals experimentally vaccinated against or infected with EBOV. Using the information obtained along with structural modeling to predict epitope accessibility, we then constructed two DNA vaccines encoding immunodominant and subdominant epitopes predicted to be accessible on EBOV GP...
July 12, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28679761/the-host-e3-ubiquitin-ligase-trim6-ubiquitinates-the-ebola-virus-vp35-protein-and-promotes-virus-replication
#6
Preeti Bharaj, Colm Atkins, Priya Luthra, Maria Isabel Giraldo, Brian E Dawes, Lisa Miorin, Jeffrey R Johnson, Nevan J Krogan, Christopher F Basler, Alexander N Freiberg, Ricardo Rajsbaum
Ebola virus (EBOV), a member of the Filoviridae family, is a highly pathogenic virus that causes severe hemorrhagic fever in humans and is responsible for epidemics throughout sub-Saharan, central and West Africa. The EBOV genome encodes for VP35, an important viral protein involved in virus replication by acting as an essential cofactor of the viral polymerase as well as a potent antagonist of the host antiviral type-I interferon (IFN-I) system. By using mass spectrometry analysis and co-immunoprecipitation assays, we show here that VP35 is ubiquitinated on lysine 309 (K309), a residue located on its IFN antagonist domain...
July 5, 2017: Journal of Virology
https://www.readbyqxmd.com/read/28675995/ebola-epidemics-control-origin-and-therapeutics
#7
Da Yong Lu, Hong Ying Wu, Nagendra Sastry Yarla, Ting-Ren Lu, Bin Xu, Jian -Ding
Ebola epidemic in Africa was outbreak again in 2014 that arises a new wave of panic worldwide. There is a high mortality rates (30-70%) among Ebola infected people in virus-stricken areas. The direct communications between affected countries and rest of world were cut off then. But the medical capabilities against this deadly viral disease were provided by a limited number of agents, several patented agents, biotherapies or prophylactic/therapeutic vaccines have been entering into clinical validations and will be further developed into the global markets-including patents of small molecular chemicals, short sequences or oligomers of DNA/RNA, linkages of chemicals with bio-molecules, herbal medicine and so on...
July 3, 2017: Infectious Disorders Drug Targets
https://www.readbyqxmd.com/read/28669593/pathogen-mimicking-vaccine-delivery-system-designed-with-a-bioactive-polymer-inulin-acetate-for-robust-humoral-and-cellular-immune-responses
#8
Hemachand Tummala, Sunny Kumar, Siddharth S Kesharwani, Bhimanna Kuppast, Mohammed Ali Bakkari
New and improved vaccines are needed against challenging diseases such as malaria, tuberculosis, Ebola, influenza, AIDS, and cancer. The majority of existing vaccine adjuvants lack the ability to significantly stimulate the cellular immune response, which is required to prevent the aforementioned diseases. This study designed a novel particulate based pathogen-mimicking vaccine delivery system (PMVDS) to target antigen-presenting-cells (APCs) such as dendritic cells. The uniqueness of PMVDS is that the polymer used to prepare the delivery system, Inulin Acetate (InAc), activates the innate immune system...
June 29, 2017: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/28663940/considerations-for-use-of-investigational-drugs-in-public-health-emergencies
#9
Matthew Carl Kirchoff, Jerome F Pierson
The paradigm for the use of investigational drugs in public health emergencies has been recently tested to prevent and treat highly infectious and lethal diseases. Examples include the successful implementation of vaccine and therapeutic clinical trials during the recent Ebola outbreak in West Africa. On the other end of the spectrum was the Emergency Use Authorization (EUA) of peramivir in the treatment of H1N1 influenza virus that did not provide an opportunity to collect data or understand the effectiveness of the EUA program...
March 2017: Therapeutic Innovation & Regulatory Science
https://www.readbyqxmd.com/read/28662754/animal-models-of-ebolavirus-infection
#10
Marisa C St Claire, Dan R Ragland, Laura Bollinger, Peter B Jahrling
Ebola virus is a highly pathogenic member of the family Filoviridae that causes a severe hemorrhagic disease in humans and NHP. The 2013-2016 West African outbreak has increased interest in the development and refinement of animal models of Ebola virus disease. These models are used to test countermeasures and vaccines, gain scientific insights into the mechanisms of disease progression and transmission, and study key correlates of immunology. Ebola virus is classified as a BSL4 pathogen and Category A agent, for which the United States government requires preparedness in case of bioterrorism...
June 1, 2017: Comparative Medicine
https://www.readbyqxmd.com/read/28659436/broad-spectrum-antiviral-gs-5734-inhibits-both-epidemic-and-zoonotic-coronaviruses
#11
Timothy P Sheahan, Amy C Sims, Rachel L Graham, Vineet D Menachery, Lisa E Gralinski, James B Case, Sarah R Leist, Krzysztof Pyrc, Joy Y Feng, Iva Trantcheva, Roy Bannister, Yeojin Park, Darius Babusis, Michael O Clarke, Richard L Mackman, Jamie E Spahn, Christopher A Palmiotti, Dustin Siegel, Adrian S Ray, Tomas Cihlar, Robert Jordan, Mark R Denison, Ralph S Baric
Emerging viral infections are difficult to control because heterogeneous members periodically cycle in and out of humans and zoonotic hosts, complicating the development of specific antiviral therapies and vaccines. Coronaviruses (CoVs) have a proclivity to spread rapidly into new host species causing severe disease. Severe acute respiratory syndrome CoV (SARS-CoV) and Middle East respiratory syndrome CoV (MERS-CoV) successively emerged, causing severe epidemic respiratory disease in immunologically naïve human populations throughout the globe...
June 28, 2017: Science Translational Medicine
https://www.readbyqxmd.com/read/28658761/ebola-vaccine-how-far-are-we
#12
REVIEW
Rajani Sharma, Ketki Jangid, Anuradha
Ebola viruses have been identified as an emerging threat as it causes severe haemorrhagic fever in human with mortality rates ranging from 50 to 90%. In addition to being a global health concern, the virus also is considered a potential biological threat agent. As for now, no licensed vaccine is available for pre or post exposure treatment. Recent epidemic of this disease in South Africa has led to concern towards development of an effective vaccine on a priority basis. This review is an attempt to look upon current progress in the development of Ebola virus vaccines and highlights strategies that have the greatest potential for commercial development...
May 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28651650/ethics-review-of-studies-during-public-health-emergencies-the-experience-of-the-who-ethics-review-committee-during-the-ebola-virus-disease-epidemic
#13
Emilie Alirol, Annette C Kuesel, Maria Magdalena Guraiib, Vânia de la Fuente-Núñez, Abha Saxena, Melba F Gomes
BACKGROUND: Between 2013 and 2016, West Africa experienced the largest ever outbreak of Ebola Virus Disease. In the absence of registered treatments or vaccines to control this lethal disease, the World Health Organization coordinated and supported research to expedite identification of interventions that could control the outbreak and improve future control efforts. Consequently, the World Health Organization Research Ethics Review Committee (WHO-ERC) was heavily involved in reviews and ethics discussions...
June 26, 2017: BMC Medical Ethics
https://www.readbyqxmd.com/read/28647168/communicating-infectious-disease-prevalence-through-graphics-results-from-an-international-survey
#14
Angela Fagerlin, Thomas S Valley, Aaron M Scherer, Megan Knaus, Enny Das, Brian J Zikmund-Fisher
BACKGROUND: Graphics are increasingly used to represent the spread of infectious diseases (e.g., influenza, Zika, Ebola); however, the impact of using graphics to adequately inform the general population is unknown. OBJECTIVE: To examine whether three ways of visually presenting data (heat map, dot map, or picto-trendline)-all depicting the same information regarding the spread of a hypothetical outbreak of influenza-influence intent to vaccinate, risk perception, and knowledge...
July 13, 2017: Vaccine
https://www.readbyqxmd.com/read/28647166/clinical-development-of-a-recombinant-ebola-vaccine-in-the-midst-of-an-unprecedented-epidemic
#15
Beth-Ann G Coller, Jeffrey Blue, Rituparna Das, Sheri Dubey, Lynn Finelli, Swati Gupta, Frans Helmond, Rebecca J Grant-Klein, Kenneth Liu, Jakub Simon, Sean Troth, Susan VanRheenen, Julie Waterbury, Ashley Wivel, Jayanthi Wolf, D Gray Heppner, Tracy Kemp, Rick Nichols, Thomas P Monath
The 2014-2016 Ebola outbreak caused over 28,000 cases and 11,000 deaths. Merck & Co. Inc., Kenilworth, NJ USA and NewLink Genetics are working with private and public partners to develop and license an Ebola vaccine that was evaluated extensively during the outbreak. The vaccine referred to as V920 is a recombinant vesicular stomatitis virus (rVSV) in which the VSV-G envelope glycoprotein (GP) is completely replaced by the Zaire ebolavirus GP (rVSVΔG-ZEBOV-GP). Eight Phase I and four Phase II/III clinical trials enrolling approximately 17,000 subjects were conducted in parallel to the outbreak to assess the safety, immunogenicity, and/or efficacy of V920...
June 21, 2017: Vaccine
https://www.readbyqxmd.com/read/28645623/identification-of-a-coumarin-based-antihistamine-as-an-anti-filoviral-entry-inhibitor
#16
Han Cheng, Adam Schafer, Veronica Soloveva, Dima Gharaibeh, Tara Kenny, Cary Retterer, Rouzbeh Zamani, Sina Bavari, Norton P Peet, Lijun Rong
Filoviruses, consisting of Ebola virus, Marburg virus and Cuevavirus, cause severe hemorrhagic fevers in humans with high mortality rates up to 90%. Currently, there is no approved vaccine or therapy available for the prevention and treatment of filovirus infection in humans. The recent 2013-2015 West African Ebola epidemic underscores the urgency to develop antiviral therapeutics against these infectious diseases. Our previous study showed that GPCR antagonists, particularly histamine receptor antagonists (antihistamines) inhibit Ebola and Marburg virus entry...
June 20, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28643203/nonhuman-primate-models-of-ebola-virus-disease
#17
Richard S Bennett, Louis M Huzella, Peter B Jahrling, Laura Bollinger, Gene G Olinger, Lisa E Hensley
Ebola virus disease (EVD) in humans is associated with four ebolaviruses: Ebola virus (EBOV), Sudan virus (SUDV), Bundibugyo virus (BDBV), and Taï Forest virus. To date, no documented cases of human disease have been associated with Reston virus. Here, we describe the nonhuman primate (NHP) models that currently serve as gold standards for testing ebolavirus vaccines and therapeutic agents and elucidating underlying mechanisms of pathogenesis. Although multiple models have been explored over the past 50 years, the predominance of published work has been performed in macaque models...
June 23, 2017: Current Topics in Microbiology and Immunology
https://www.readbyqxmd.com/read/28642489/post-exposure-treatment-of-non-human-primates-lethally-infected-with-ebola-virus-with-ebotab-a-purified-ovine-igg-product
#18
Stuart D Dowall, Frédéric Jacquot, John Landon, Emma Rayner, Graham Hall, Caroline Carbonnelle, Hervé Raoul, Delphine Pannetier, Ian Cameron, Ruth Coxon, Ibrahim Al Abdulla, Roger Hewson, Miles W Carroll
Despite sporadic outbreaks of Ebola virus (EBOV) over the last 4 decades and the recent public health emergency in West Africa, there are still no approved vaccines or therapeutics for the treatment of acute EBOV disease (EVD). In response to the 2014 outbreak, an ovine immunoglobulin therapy was developed, termed EBOTAb. After promising results in the guinea pig model of EBOV infection, EBOTAb was tested in the cynomolgus macaque non-human primate model of lethal EBOV infection. To ensure stringent therapeutic testing conditions to replicate likely clinical usage, EBOTAb was first delivered 1, 2 or 3 days post-challenge with a lethal dose of EBOV...
June 22, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28630358/assessing-the-safety-and-immunogenicity-of-recombinant-vesicular-stomatitis-virus-ebola-vaccine-in-healthy-adults-a-randomized-clinical-trial
#19
RANDOMIZED CONTROLLED TRIAL
May S ElSherif, Catherine Brown, Donna MacKinnon-Cameron, Li Li, Trina Racine, Judie Alimonti, Thomas L Rudge, Carol Sabourin, Peter Silvera, Jay W Hooper, Steven A Kwilas, Nicole Kilgore, Christopher Badorrek, W Jay Ramsey, D Gray Heppner, Tracy Kemp, Thomas P Monath, Teresa Nowak, Shelly A McNeil, Joanne M Langley, Scott A Halperin
BACKGROUND: The 2013-2016 Ebola virus outbreak in West Africa was the most widespread in history. In response, alive attenuated recombinant vesicular stomatitis virus (rVSV) vaccine expressing Zaire Ebolavirus glycoprotein (rVSVΔG-ZEBOV-GP) was evaluated in humans. METHODS: In a phase 1, randomized, dose-ranging, observer-blind, placebo-controlled trial, healthy adults aged 18-65 years were randomized into 4 groups of 10 to receive one of 3 vaccine doses or placebo...
June 19, 2017: CMAJ: Canadian Medical Association Journal, Journal de L'Association Medicale Canadienne
https://www.readbyqxmd.com/read/28616501/searching-for-animal-models-and-potential-target-species-for-emerging-pathogens-experience-gained-from-middle-east-respiratory-syndrome-mers-coronavirus
#20
REVIEW
Júlia Vergara-Alert, Enric Vidal, Albert Bensaid, Joaquim Segalés
Emerging and re-emerging pathogens represent a substantial threat to public health, as demonstrated with numerous outbreaks over the past years, including the 2013-2016 outbreak of Ebola virus in western Africa. Coronaviruses are also a threat for humans, as evidenced in 2002/2003 with infection by the severe acute respiratory syndrome coronavirus (SARS-CoV), which caused more than 8000 human infections with 10% fatality rate in 37 countries. Ten years later, a novel human coronavirus (Middle East respiratory syndrome coronavirus, MERS-CoV), associated with severe pneumonia, arose in the Kingdom of Saudi Arabia...
June 2017: One Health
keyword
keyword
41124
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"